Publications by authors named "Stephen Marder"

Claim this Profile
E
Efficacy and safety of iclepertin for cognitive impairment associated with schizophrenia (CONNEX programme): results from three phase 3 randomised controlled trials.
Richard S E Keefe, Philip D Harvey, Christoph U Correll, Peter Falkai, Naoki Hashimoto, Stephen Marder

Lancet Psychiatry· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychosocial Interventions and Functional Recovery in Schizophrenia-Realizing Opportunities Today.
Rajiv Tandon, Deanna M Barch, Robert W Buchanan, Michael F Green, Matcheri S Keshavan, Stephen R Marder

J Clin Psychiatry· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.
Oliver D Howes, Bernard R Bukala, Eric Y H Chen, Christoph U Correll, Alkomiet Hasan, Stephen R Marder

Am J Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dopamine-Blocking Antipsychotics-Time for a New Conversation With Patients?
Stephen R Marder, Sean Ostlund

JAMA Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In These Times.
James M Gold, Laura Rowland, Sonia Bansal, Philip Harvey, Janet Smith, Stephen Marder

Schizophr Bull· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms.
Dragana Bugarski-Kirola, I-Yuan Liu, Celso Arango, Stephen R Marder

Schizophr Bull· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Streamlining the Pathway Toward Approval of a Cognition Enhancer for Schizophrenia.
Keith H Nuechterlein, Michael F Green, Stephen R Marder

Schizophr Bull· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
William P Horan, Steven D Targum, Amy Claxton, Inder Kaul, Samantha E Yohn, Stephen R Marder

Schizophr Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does relapse cause illness progression in first-episode psychosis? A review.
Kevin P Kennedy, Michael F Zito, Stephen R Marder

Schizophr Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implementation of Cognitive Behavioral Therapy for psychosis via telehealth: An expert consultation and clinical service model.
Marci L Gaither, Elena D Bassett, Amy L Wilson, Stephen R Marder, Daniel W Bradford

Psychol Serv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial.
Yuki Mukai, Robert Lupinacci, Stephen Marder, Linda Snow-Adami, Tiffini Voss

Schizophr Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive Dyskinesia.
Christoph U Correll, Leslie Citrome, Carlos Singer, Jean-Pierre Lindenmayer, Celia Zinger, Stephen R Marder

J Clin Psychopharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.
Spyridon Siafis, Lasse Brandt, Robert A McCutcheon, Stefan Gutwinski, Johannes Schneider-Thoma, Stephen R Marder

Lancet Psychiatry· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive Impairment Associated With Schizophrenia: New Research Agenda.
Silvana Galderisi, Stephen R Marder

Schizophr Bull Open· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms.
David Gordon Daniel, Alex S Cohen, Philip D Harvey, Dawn I Velligan, William Z Potter, Stephen R Marder

Schizophr Bull Open· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychosis among individuals with methamphetamine use disorder is associated with elevated rates of hospitalizations and emergency department visits across an academic health care system.
Michael F Zito, Zhe Fei, Yuhui Zhu, Sarah E Clingan, Stephen R Marder

J Subst Use Addict Treat· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments.
Stephen R Marder, Daniel Umbricht

Schizophr Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antipsychotic discontinuation and recovery: chicken or egg?
Joseph M Pierre, Michael F Zito, Yvonne S Yang, Stephen R Marder

Psychol Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Remote Assessment of Negative Symptoms of Schizophrenia.
David G Daniel, Alex S Cohen, Dawn Velligan, Phillip D Harvey, Larry Alphs, Stephen R Marder

Schizophr Bull Open· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study.
Yvonne S Yang, Richard J Maddock, Huailin Zhang, Junghee Lee, Gerhard Hellemann, Stephen R Marder

Psychiatry Res Neuroimaging· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural Language Processing: Its Potential Role in Clinical Care and Clinical Research.
Stephen R Marder

Schizophr Bull· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications.
Ira R Katz, Benjamin R Szymanski, Stephen R Marder, Abigail Shotwell, Tyler C Hein

Psychiatry Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare coding variants in ten genes confer substantial risk for schizophrenia.
Tarjinder Singh, Timothy Poterba, David Curtis, Huda Akil, Mariam Al Eissa, Stephen R Marder

Nature· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping genomic loci implicates genes and synaptic biology in schizophrenia.
Vassily Trubetskoy, Antonio F Pardiñas, Ting Qi, Georgia Panagiotaropoulou, Swapnil Awasthi, Stephen R Marder

Nature· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to Stop Using the Term Relapse in Schizophrenia Clinical Trials.
William T Carpenter, Robert W Buchanan, Stephen R Marder

Schizophr Bull Open· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis